Effects of lenvatinib on in vivo angiogenesis induced by KP-1/VEGF and KP-1/FGF transfectants. (A) In vivo angiogenesis in mouse DAS assay. Angiogenesis was induced by overexpressed human VEGF121 (KP-1/VEGF) or mouse FGF4 (KP-1/FGF) in human pancreatic cancer KP-1 cells at the mouse dorsal skin. Representative photographs are shown. (B) Effect of lenvatinib and sorafenib on the VEGF- and FGF-driven in vivo angiogenesis in mouse DAS assay. Compounds were administered orally once daily for 4 days at the indicated doses. Data are the mean ± std. *: p < 0.05 and **: p < 0.01 compared to vehicle.